The combination of BCL-xL PROTAC and mTOR inhibitor sensitizes pancreatic ductal adenocarcinoma to KRASG12D inhibitor treatment by enhancing apoptosis induction
Javed Miyan, Vignesh Vudatha, Lin Cao, Peiyi Zhang, Guangrong Zheng, Lei Zheng, Jose Trevino, Daohong Zhou, Sajid Khan
This paper shows that combining BCL-xL PROTAC and mTOR inhibitor with KRASG12D inhibitor enhances apoptosis and overcomes resistance in PDAC.
bioRxiv · Jan 5, 2026 · PreprintCancer Biology